Synchronized disappearance of serum HCV-RNA, anti-U1 RNP, anti-La/SS-B, and anti-Scl-70 in a patient with chronic hepatitis

Omagari, Katsuhisa; Matsuo, Isao; Ohba, Kazuo; Masuda, Junichi; Hazama, Hiroaki; Sakimura, Kanae; Kinoshita, Hideki; Tsurutani, Hiroko; Isomoto, Hajime; Murase, Kunihiko; Kohno, Shigeru

doi:10.1016/s1386-6346(00)00114-5

Cited by 3 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously postulated that the simultaneous disappearance of HCV-RNA, anti-U1 RNP, anti-La/SS-B and anti-Scl-70 antibodies in a patient with chronic hepatitis without treatment of IFN, [4] was probably because these anti-ENAs represented a HCV-associated autoimmunity, or the immunomodulating effects of ursodeoxycholic acid. Akashi et al [5] also reported another patient with chronic hepatitis C in whom HCV-RNA, anti-U1 RNP and anti-La/SS-B antibodies disappeared after CR to IFN treatment.…”

Section: Discussionmentioning

confidence: 99%

“…We have previously reported a case of chronic hepatitis in whom normalization of serum aminotransferases was associated with disappearance of serum hepatitis C virus (HCV)-ribonucleic acid (RNA), anti-U1 RNP, anti-La/SS-B and anti-Scl-70 antibodies without treatment with interferon (IFN) or corticosteroids. [4] Akashi et al [5] also recently reported a patient with chronic hepatitis C in whom ANA, anti-U1 RNP and antiLa/SS-B antibodies disappeared after complete response (CR) to IFN treatment. These two reports suggest that anti-ENA antibodies could be associated with HCV infection.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-extractable Nuclear Antigens (ENA) Antibodies in Patients with Chronic Hepatitis C before and after Treatment with Interferon

et al. 2003

View full text Add to dashboard Cite

A high prevalence of serological markers classically associated with autoimmune hepatitis or other autoimmune diseases has been reported in patients with chronic hepatitis C. However, the prevalence of antibodies to extractable nuclear antigens (anti-ENA) are rarely reported in such patients and the effect of treatment with interferon (IFN) on their prevalence is not known. In the present study, serum samples collected from 44 patients with chronic hepatitis C and 44 patients with non-hepatitis C virus (HCV) infected liver diseases were tested for anti-ENAs (U1 RNP, Sm, Ro/SS-A, La/SS-B and Scl-70) antibodies by enzyme-linked immunosorbent assay (ELISA). In 26 patients with chronic hepatitis C who received IFN treatment, serum samples were also collected just after completion of IFN treatment, and/or at 6-40 months after completion of the treatment, and tested for these antibodies. Sixteen (36%) of 44 sera from patients with chronic hepatitis C were positive for at least one of the above anti-ENA antibodies, whereas only 7 (16%) of 44 sera from patients with non-HCV infected liver diseases were positive for such antibodies (p = 0.0290). There was no significant difference in the prevalence of each of anti-ENA antibody between men and women. Results of anti-ENA antibodies in most IFN-treated patients with chronic hepatitis C did not change after treatment. However, in some cases serum anti-U1 RNP, anti-La/SS-B and anti-Scl-70 became negative or converted to the gray zone after completion of IFN treatment regardless of HCV elimination. Our results showed that the overall prevalence of anti-ENA antibodies was significantly higher in patients with chronic hepatitis C than in those with non-HCV-infected liver diseases. However, the disappearance of anti-ENA antibodies after IFN treatment in patients with chronic hepatitis C may be due to the immunomodulating effects of IFN rather than HCV elimination.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Anti-extractable Nuclear Antigens (ENA) Antibodies in Patients with Chronic Hepatitis C before and after Treatment with Interferon

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Anti-Scl 70 antibodies are directed to a fraction of a DNA-bound protein (topoisomerase I), being infrequently present in collagen-vascular diseases other than scleroderma. They are rarely found in SLE patients with anti-DNA antibodies, SLE associated to sicca syndrome, and chronic hepatitis C. Anti-Scl 70 antibodies are associated with nephritis and pulmonary hypertension [6][7][8]. The presence of anti-Scl 70 antibodies in localized scleroderma is not frequent but is often seen in diffuse scleroderma, particularly in cases with lung involvement (hypertension or fibrosis) [9].…”

Section: Discussionmentioning

confidence: 99%

Fever of unknown origin secondary to type I crescentic glomerulonephritis and anti-SCl 70 antibodies without clinical manifestations of systemic sclerosis

2008

View full text Add to dashboard Cite

A 57-year-old woman presented with fever and cellulitis of the right leg. Urinalysis and kidney function were normal on admission. Cellulitis remitted but fever persisted for six weeks. X-ray imaging, cultures, serological assays for viruses and autoimmunity did not reveal the cause of fever. Unexpectedly anti-Scl 70 (anti-topoisomerase I) antibodies were positive. A skin biopsy ruled out scleroderma. On the fifth hospitalization week kidney function declined in association with hematuria, leucocyturia, and proteinuria. Prednisone was administered due to clinical suspicion of drug-induced interstitial nephritis. Fever declined in 24 h, but renal failure became rapidly worse requiring hemodialysis. Kidney biopsy revealed extensive crescentic glomerulonephritis (CGN), with much glomerular destruction, with an IgG-positive linear pattern on immunofluorescence microscopy. No overtly active microangiopathy or vasculitis were present. There was no pulmonary involvement and anti-glomerular basement membrane antibodies were not detected in the serum. After one year anti-Scl 70 antibodies were still positive without scleroderma manifestations and 17 months later the patient received a kidney transplant with excellent results. Presentation of type 1 CGN as a fever of unknown origin (FUO) is exceptional. Anti-Scl 70 antibodies are highly specific for scleroderma and are seldom present in other diseases. As far as we are aware there are no published cases of the association of type 1 CGN with anti-Scl 70 antibodies.

show abstract

“…the ability of a virus to replicate under the selective forces present in its environment 16 ) or an enhancement of anti-HCV host defences has been hypothesized to precede viral clearance: presence of very large liver cancers able to reduce the number of infected cells, 8 immune response restoration, 12,13 HBV superinfection, 9 use of immunomodulant drugs 10,11 and pregnancy.…”

Section: Late Post-therapy Hcv-rna Clearance 1043mentioning

confidence: 99%

A 5‐year prospective study of the late resolution of chronic hepatitis C after antiviral therapy

Annicchiarico

Siciliano

Avolio³

et al. 2007

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Synchronized disappearance of serum HCV-RNA, anti-U1 RNP, anti-La/SS-B, and anti-Scl-70 in a patient with chronic hepatitis

Cited by 3 publications

References 17 publications

Anti-extractable Nuclear Antigens (ENA) Antibodies in Patients with Chronic Hepatitis C before and after Treatment with Interferon

Anti-extractable Nuclear Antigens (ENA) Antibodies in Patients with Chronic Hepatitis C before and after Treatment with Interferon

Fever of unknown origin secondary to type I crescentic glomerulonephritis and anti-SCl 70 antibodies without clinical manifestations of systemic sclerosis

A 5‐year prospective study of the late resolution of chronic hepatitis C after antiviral therapy

Contact Info

Product

Resources

About